• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection and Management in Pharmacovigilance
  • News
  • Opinion
  • About
  • Glossary

Deep Learning, Machine Learning, and Artificial Intelligence – What are the Differences?

March 18, 2018 by Jose Rossello 1 Comment

In this video, Bernardo F. Nunes explains how these 3 concepts (artificial intelligence, machine learning, and deep learning) do not represent the same thing:

Bernardo is breaking down the 3 concepts for us, in a very easy and understandable way.

Artificial intelligence exists when a machine has cognitive capabilities, such as problem solving and learning. It’s normally associated to a human benchmark, as, for example reasoning, speech, and vision.

In the video, he differentiates 3 levels of A.I.:

  1. Narrow A.I., when a machine is better than us in a specific task (we are here now)
  2. General A.I., when a machine is like us in any intellectual task
  3. Strong A.I, when a machine is better than us in many tasks

One of the favorites early developments in A.I. is the perceptron (1957). It was a single layer of artificial neural networks designed for image recognition. They are called neural networks because the first practitioners on A.I. thought that these interconnected nodes looked like the human neural system, which has neural networks. These are the natural neural networks. The perceptron is a rudimentary version of an artificial neural network.

Machine learning, appeared on the 1980s, when a body of researchers worked on what is called supervised learning. Algorithms are trained with datasets based on past examples, in a model in which the trained algorithm is applied to a new dataset for classification purposes. Widely used for business purposes.

Deep learning makes use of deep neural networks. Shallow neural nets have only one hidden layer between the input and the output. However, deep neural nets have 2 or more hidden layers between the input and the output. It’s the responsible for the advancement in image recognition. If you can represent an image numerically, then you can process it with deep learning.

Bernardo’s conclusion is that deep learning, machine learning, and artificial intelligence are not 3 different things. They simply are subsamples of each other: deep learning belongs to machine learning, and machine learning belongs to artificial intelligence.

Jose Rossello
Jose Rossello

Related posts:

  1. The Pharmacovigilance of the Future: Prospective, Proactive, and Predictive
  2. Analysis Of Textual Data May Complement Traditional Pharmacovigilance
  3. The Proportional Reporting Ratio According to ChatGPT
  4. Predictive Models for Identifying Drug Risks: Enhancing Pharmaceutical Safety

Filed Under: PV Analytics Tagged With: AI, artificial intelligence, deep learning, machine learning

Reader Interactions

Trackbacks

  1. Machine Learning and Pharmacovigilance - Pharmacovigilance Analytics says:
    November 20, 2023 at 12:54 am

    […] are different machine learning models, and all of them can be applied to pharmacovigilance analytics. Here we are talking about […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe in a reader

Search Website

Uses of Generative AI in Pharmacovigilance

Featured News / Posts

Signal Analytics Technology in Pharmacovigilance

Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

Pharmacovigilance plays a crucial role in ensuring public safety by monitoring, … [Read More...] about Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

8 Common FDA Applications for Drugs & Biologics

The U.S. Food and Drug Administration (FDA) has several types of applications … [Read More...] about 8 Common FDA Applications for Drugs & Biologics

Key IND Enabling Studies: Navigating Preclinical Development Regulations

Investigational New Drug (IND) applications represent a critical stage in the … [Read More...] about Key IND Enabling Studies: Navigating Preclinical Development Regulations

Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Pharmacokinetics and pharmacodynamics are two fundamental pillars in the field … [Read More...] about Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Regulatory authorities in the pharmaceutical industry have established standards … [Read More...] about Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

In the realm of patient safety and pharmacovigilance, statistical signal … [Read More...] about Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

Pharmacovigilance signal detection software plays a crucial role in … [Read More...] about Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

A Periodic Benefit-Risk Evaluation Report (PBRER) serves as a structured … [Read More...] about What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Drug safety and pharmacovigilance are crucial aspects of public … [Read More...] about Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

he Development Safety Update Report (DSUR) is a crucial document that serves as … [Read More...] about Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

  • What is a DSUR (Development Safety Update Report)? An Essential Guide for Clinical Research
  • What is a BLA (Biologics License Application)? Essential Guide for Professionals
  • What is a PADER? – Periodic Adverse Drug Experience Report Explained

RSS ICH News

  • An error has occurred, which probably means the feed is down. Try again later.

RSS From Nature journal

  • A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development
  • Description of barriers to the deprescription of inappropriate drugs in French hospitalized geriatric services
  • The association between antenatal indomethacin exposure and persistent pulmonary hypertension of the newborn in extremely preterm infants
  • Synergistic effect of synthetic derivatives of 1,3,4-thiadiazole with amphotericin B in antifungal therapy
  • A pharmacovigilance analysis of post-marketing safety of durvalumab

Copyright © 2025 · News Pro on Genesis Framework · WordPress · Log in